NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.64 +0.16 (+0.20%) GOLD FUTURES
2,321.90 -9.30 (-0.40%) DOW
38,872.18 +19.91 (+0.05%) Bitcoin GBP
50,557.52 +42.76 (+0.08%)
GenSight Biologics S.A. (GSGTF)
| Previous close | 0.4500 |
| Open | 0.4800 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 0.4500 - 0.4500 |
| 52-week range | 0.0003 - 3.1000 |
| Volume | |
| Avg. volume | 12 |
| Market cap | 35.112M |
| Beta (5Y monthly) | 2.14 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5800 |
| Earnings date | 22 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireGenSight Biologics Announces the Availability of a Prospectus in Connection With the Listing of New Shares on Euronext Paris
PARIS, May 07, 2024--Regulatory News: THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA
Business WireGenSight Biologics: Annual General Meeting on May 29, 2024
PARIS, May 07, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 29, 2024, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France.
Business WireGenSight Biologics Announces a Successful Offering for an Amount Over €9.2 Million
PARIS, May 07, 2024--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the "Company"), a biopharma Company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today the resumption of the trading of the Company’s shares following the success of its Offering (as defined below), through (i) a capital increase reserved to specialized investors and (ii) a c
